correct logo mayzent.jpg
novartis_rm_logo_pos_rgb.png

 

We are delighted to welcome you to join us for this virtual meeting:

UK real world experience with MAYZENT▼ (siponimod) in SPMS patients with active disease

19th October 2021

5:00-6:00pm

gradient button 175.png
gradient button 140.png
gradient button.png
02.png

MAYZENT is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity.

gradient strip.png

This promotional meeting intended for UK HCPs is organised and funded by Novartis Pharmaceuticals UK Ltd.

UK | October 2021 | 157857

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.UK/yellowcard.

Adverse events should also be reported to Novartis via uk.patientsafety@novartis.com or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com.

If you have a question about the product, please contact Medical Information on 01276 698370 or by email at medinfo.uk@novartis.com